Premium
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
Author(s) -
Zamorano Jose Luis,
Lancellotti Patrizio,
Rodriguez Muñoz Daniel,
Aboyans Victor,
Asteggiano Riccardo,
Galderisi Maurizio,
Habib Gilbert,
Lenihan Daniel J.,
Lip Gregory Y. H.,
Lyon Alexander R.,
Lopez Fernandez Teresa,
Mohty Dania,
Piepoli Massimo F.,
Tamargo Juan,
Torbicki Adam,
Suter Thomas M.,
Zamorano Jose Luis,
Aboyans Victor,
Achenbach Stephan,
Agewall Stefan,
Badimon Lina,
BarónEsquivias Gonzalo,
Baumgartner Helmut,
Bax Jeroen J.,
Bueno Héctor,
Carerj Scipione,
Dean Veronica,
Erol Çetin,
Fitzsimons Donna,
Gaemperli Oliver,
Kirchhof Paulus,
Kolh Philippe,
Lancellotti Patrizio,
Lip Gregory Y. H.,
Nihoyannopoulos Petros,
Piepoli Massimo F.,
Ponikowski Piotr,
Roffi Marco,
Torbicki Adam,
Vaz Carneiro António,
Windecker Stephan
Publication year - 2017
Publication title -
european journal of heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.149
H-Index - 133
eISSN - 1879-0844
pISSN - 1388-9842
DOI - 10.1002/ejhf.654
Subject(s) - medicine , heart failure , position paper , cardiac toxicity , cancer , intensive care medicine , toxicity , pathology
Clinically overt heart failure is common, costly, disabling, and deadly; it remains so despite the tremendous benefit of angiotensin-convertin enzyme inhibitors. Better treatments for and earlier detection of heart failure are needed if the situation to improve. However, even this may not be enough. The dramatic deterioration in quality of life and prognosis when a patient progresses from asymptomatic left ventricular dysfunction to overt heart failure suggests that only a programme of screening and prevention will effectively reduce the public health burden of heart failure. Moreover, the economic consequences of developing overt heart failure suggest that such an approach is likely to be cost-effective.